Can NT-proBNP monitoring help prevent cardiovascular disease?

被引：0

作者：

Campbell, D. J. ^{[1
,2
]}

Woodward, M. ^{[3
]}

Chalmers, J. P. ^{[3
]}

Colman, S. A. ^{[3
]}

Jenkins, A. J. ^{[2
]}

Kemp, B. E. ^{[1
]}

Neal, B. C. ^{[3
]}

Patel, A. ^{[3
]}

MacMahon, S. W. ^{[3
]}

机构：

[1] Univ Melbourne, St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic, Australia

[2] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic, Australia

[3] Univ Sydney, George Inst Int Hlth, Camperdown, NSW, Australia

来源：

RECENT ADVANCES IN CARDIOVASCULAR DISEASE: PROCEEDINGS OF THE 13TH WORLD CONGRESS HEART DISEASE | 2007年

基金：

澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In subjects with cerebrovascular disease, plasma NT-proBNP levels assist the identification of increased risk for congestive heart failure, myocardial infarction, and ischemic stroke. Given that perindopril-based blood pressure-lowering therapy reduced the risk of these events, we investigated whether it also reduced NT-proBNP levels. Blood pressure reduction was similar for subjects with different baseline levels of NT-proBNP and was associated with reduced NT-proBNP levels in those subjects with elevated NT-proBNP (> 26 pmol/L), with a median reduction of 16 pmol/L (interquartile range 0-51 pmol/L, P=0.004), corresponding to a median decrease of 39% (interquartile range 0-69%). We conclude that plasma NT-proBNP level, in addition to predicting cardiovascular risk, may provide a measure of risk reduction by blood pressure-lowering therapy.

引用

页码：331 / +

页数：3

共 50 条

[11] Nt-proBNP predicts cardiovascular complications in pregnant women with congenital heart disease
Kampman, M. A. M.
Balci, A.
Mulder, B. J. M.
Van Dijk, A. P. J.
Roos-Hesselink, J. W.
Sollie-Szarynska, K. M.
Ludwig-Ruitenberg, M.
Van Melle, J. P.
Van Veldhuisen, D. J.
Pieper, P. G.
[J]. EUROPEAN HEART JOURNAL, 2013, 34 : 378 - 378
[12] VALUE OF MONITORING BNP AND NT-PROBNP ABOUT CARDIOVASCULAR EVENTS IN MAINTENANCE HEMODIALYSIS PATIENTS
Sheng, Xiaohua
Yu, Gang
Fei, Yang
Bao, Hongda
Yin, Jianyong
Wang, Niansong
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
[13] BNP or NT-proBNP?
不详
[J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2004, 42 (10) : A104 - A104
[14] A comparison of BNP and NT-proBNP in the disease monitoring of heart failure patients.
Hammerer-Lercher, AM
Falkensammer, G
Ludwig, W
Pölzl, G
Hügel, H
Pachinger, O
Puschendorf, B
Mair, J
[J]. CLINICAL CHEMISTRY, 2003, 49 (06) : A65 - A66
[15] Evaluation of NT-proBNP in Inflammatory Bowel Disease
Wacrenier, A.
Bourgeois, A. -M.
Ausseil, J.
Szymanski, C.
Thiebault, H.
Brazier, F.
Galmiche, A.
Nguyen-Khac, E.
Dupas, J. -L.
Colombel, J. -f.
Fumery, M.
[J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 : S123 - S123
[16] Evaluation of NT-proBNP in Inflammatory Bowel Disease
Wacrenier, Adrien
Bourgeois, Anne-Marie
Ausseil, Jerome
Szymanski, Catherine
Thiebault, Henri
Brazier, Franck
Galmiche, Antoine
Khac, Eric Nguyen
Dupas, Jean-Louis
Colombel, Jean-Frederic
Fumery, Mathurin
[J]. GASTROENTEROLOGY, 2015, 148 (04) : S451 - S451
[17] NT-proBNP in heart failure: therapy decisions and monitoring
Richards, M
Troughton, RW
[J]. EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (03) : 351 - 354
[18] Usefulness of monitoring of NT-proBNP in predicting of outcome in patients
Fijalkowska, A.
Kurzyna, M.
Kacprzak, A.
Florczyk, M.
Szewczyk, G.
Zygier, M.
Wawrzynska, L.
Torbicki, A.
[J]. EUROPEAN HEART JOURNAL, 2006, 27 : 617 - 618
[19] Interview: NT-proBNP: Therapy Monitoring in Heart Failure
Leitner, H.
Moertl, Deddo
[J]. JOURNAL FUR KARDIOLOGIE, 2018, 25 (7-8): : 210 - 210
[20] NT-proBNP and exercise
Chatha, Kamaljit
Alsoud, Mahrous
Griffiths, Melanie J.
Elfatih, Abubaker
Horton, Richard C.
Dunmore, Simon J.
Gama, Rousseau
[J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2006, 43 : 240 - 240

← 1 2 3 4 5 →